
Chiome Bioscience (4583) Reports Earnings: Revenue Up 8.7% YoY
StockClub
公開日時: Aug 13, 2026, 07:41 AM
Sentiment Analysis
Chiome Bioscience (4583) has released its financial results, reporting revenue up 8.7% YoY to 273 million yen. On the profit front, the company posted an operating loss of 479 million yen, ordinary loss of 481 million yen, and a net loss of 483 million yen. Basic earnings per share (EPS) stood at -6.62 yen.
From a financial and valuation perspective, the equity ratio is 81.9%, with interest-bearing debt at 70 million yen and retained earnings at -2.0 billion yen. EBITDA was recorded at -980 million yen, with a Return on Equity (ROE) of -65.13% and a Return on Assets (ROA) of -46.84%. As a drug discovery biotech firm, monitoring future research and development milestones, monetization progress, and financial dynamics remains essential.
個別の投資に関する推奨やアドバイスを提供することを意図しておりません。ここで述べられている意見や見解は、あくまでも各記事の個人的見解です。